Lorenz Bastian
Overview
Explore the profile of Lorenz Bastian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
252
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lazaro-Navarro J, Alcon C, Dorel M, Alasfar L, Bastian L, Baldus C, et al.
Cancer Med
. 2025 Jan;
14(1):1-7.
PMID: 39791538
Background: CREB binding protein (CREBBP) is a key epigenetic regulator, altered in a fifth of relapsed cases of acute lymphoblastic leukemia (ALL). Selectively targeting epigenetic signaling may be an effective...
2.
Whole-Exome Sequencing, Mutational Signature Analysis, and Outcome in Multiple Myeloma-A Pilot Study
Oelschlager L, Kunstner A, Frey F, Leitner T, Leypoldt L, Reimer N, et al.
Int J Mol Sci
. 2025 Jan;
25(24.
PMID: 39769182
The complex and heterogeneous genomic landscape of multiple myeloma (MM) and many of its clinical and prognostic implications remains to be understood. In other cancers, such as breast cancer, using...
3.
Neumann M, Beder T, Bastian L, Hanzelmann S, Bultmann M, Wolgast N, et al.
Leukemia
. 2024 May;
38(6):1213-1222.
PMID: 38744920
In contrast to B-cell precursor acute lymphoblastic leukemia (ALL), molecular subgroups are less well defined in T-lineage ALL. Comprehensive studies on molecular T-ALL subgroups have been predominantly performed in pediatric...
4.
Bastian L, Beder T, Barz M, Bendig S, Bartsch L, Walter W, et al.
Blood
. 2023 Dec;
143(14):1391-1398.
PMID: 38153913
Distinct diagnostic entities within BCR::ABL1-positive acute lymphoblastic leukemia (ALL) are currently defined by the International Consensus Classification of myeloid neoplasms and acute leukemias (ICC): "lymphoid only", with BCR::ABL1 observed exclusively...
5.
Spory L, Zimmermann J, Vossen-Gajcy M, Beder T, Bastian L, Alsadeq A, et al.
Hemasphere
. 2023 Sep;
7(9):e945.
PMID: 37670804
No abstract available.
6.
Beder T, Hansen B, Hartmann A, Zimmermann J, Amelunxen E, Wolgast N, et al.
Hemasphere
. 2023 Aug;
7(9):e939.
PMID: 37645423
Current classifications (World Health Organization-HAEM5/ICC) define up to 26 molecular B-cell precursor acute lymphoblastic leukemia (BCP-ALL) disease subtypes by genomic driver aberrations and corresponding gene expression signatures. Identification of driver...
7.
Hugendieck G, Lettau M, Andreas S, Neumann S, Reinhardt N, Arnold P, et al.
J Extracell Vesicles
. 2023 Jul;
12(7):e12338.
PMID: 37408115
Ovarian cancer (OvCa) is the gynaecological disorder with the poorest prognosis due to the fast development of chemoresistance. We sought to connect chemoresistance and cancer cell-derived extracellular vesicles (EV). The...
8.
Lustig M, Chan C, Jansen J, Brautigam M, Kolling M, Gehlert C, et al.
Front Immunol
. 2023 Jun;
14:1178817.
PMID: 37346044
Upregulation of surface expressed sialoglycans on tumor cells is one of the mechanisms which promote tumor growth and progression. Specifically, the interactions of sialic acids with sialic acid-binding immunoglobulin-like lectins...
9.
Darzentas F, Szczepanowski M, Kotrova M, Hartmann A, Beder T, Gokbuget N, et al.
Front Immunol
. 2023 May;
14:1125017.
PMID: 37143651
Introduction: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination...
10.
Liebig S, Neumann M, Silva P, Ortiz-Tanchez J, Schulze V, Isaakidis K, et al.
Sci Rep
. 2023 Jan;
13(1):972.
PMID: 36653435
FAT atypical cadherin 1 (FAT1), a transmembrane protein, is frequently mutated in various cancer types and has been described as context-dependent tumor suppressor or oncogene. The FAT1 gene is mutated...